Please assess the completion status of the following clinical trial:

Trial Title: Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Previously diagnosed with primary breast cancer~* Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane), either as initial therapy or after prior tamoxifen citrate, including treatment received as part of clinical trial CAN-NCIC-MA17~  * Completed aromatase inhibitor therapy ≤ 2 years ago~* No metastatic or recurrent disease, contralateral breast cancer, or ductal carcinoma in situ in either breast, as determined by the following:~  * Clinical examination of the breast area, axillae, and neck within the past 60 days~ * Mammogram within the past 12 months\*~ * Chest x-ray within the past 60 days~ * Bone scan, if alkaline phosphatase \> 2 times normal and/or there are symptoms of metastatic disease AND confirmatory x-ray, if bone scan results are questionable, within the past 60 days~ * Abdominal ultrasound, liver scan, or CT scan of the abdomen within the past 60 days, if ALT, AST, or alkaline phosphatase \> 2 times normal NOTE: \*A baseline mammogram is not required for patients who have undergone bilateral complete mastectomy~* Hormone-receptor status:~  * Estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) primary tumor at the time of diagnosis, defined as a tumor receptor content of \> 10 fmol/mg protein or receptor positive by immunocytochemical assay (for patients not previously enrolled on clinical trial CAN-NCIC-MA17)~ * ER+ and/or PR+ primary tumor OR hormone receptor status of primary tumor unknown (for patients previously enrolled on clinical trial CAN-NCIC-MA17)~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* ECOG performance status 0-2~* Life expectancy ≥ 5 years~* WBC \> 3.0 x 10\^9/L OR granulocyte count (polymorphs + bands) ≥ 1.5 times 10\^9/L~* Platelet count \> 100 x 10\^9/L~* AST and/or ALT \< 2 times upper limit of normal (ULN)\*~* Alkaline phosphatase \< 2 times ULN\*~* Able (i.e. sufficiently fluent) and willing to complete quality-of-life questionnaires in either English or French (NCIC CTG participating centers)~  * Inability to complete questionnaires due to illiteracy in English or French, loss of sight, or other equivalent reason allowed~* Accessible for treatment and follow-up~* No other prior or concurrent malignancy except adequately treated, superficial squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or other cancer treated \> 5 years ago that is presumed cured NOTE: \*Elevated levels allowed provided imaging examinations have ruled out metastatic disease~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No concurrent selective estrogen receptor modulator (e.g., raloxifene, idoxifene)~* No other concurrent anticancer therapy

- Gender: FEMALE
- Minimum Age: 0 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Letrozole (Type: EXPERIMENTAL): Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).